推荐活动

Sequenom和科罗拉多大学医学院将评估液体活检技术

首页 » 产业 » 行业 2015-10-29 转化医学网 赞(2)
分享: 
导读
Sequenom近日宣布,其将和丹佛科罗拉多大学医学院合作,以前研究该公在黑色素瘤患者身上使用的液体活检检验技术。

  Sequenom近日宣布,其将和丹佛科罗拉多大学医学院合作,以前研究该公在黑色素瘤患者身上使用的液体活检检验技术。

  作为合作的一部分,合作伙伴们将评估Sequenom的技术,能够通过循环的肿瘤DNA文本来监测黑色素瘤患者的治疗反应和复发情况。
  Sequenom的CMO  Daniel Grosu补充道,该研究是该公司第一次将关注点集中在黑色素瘤上,这将扩展Sequenom使用的技术在肿瘤和临床护理方面的使用范围。
  Sequenom目前正在研发只用于研究的检测,其一开始主要关注在非血液恶性肿瘤的晚期检测和分子分析。该公司表示,检测将覆盖大量的癌症,并分析超过100个癌症相关的基因,而这些基因都是美国食品和药物管理局(FDA)批准的有关药物治疗的靶点,并且包括了专业的群体治疗指南,其与目前正在进行临床实验,或者证据确凿的一部分癌症通路具有相关性。

  这笔交易是该公司本月的第三笔活体技术交易。上周,Sequenom和汉堡大学医学中心签署了评估结肠癌技术的协议,而本月早些时候,该公司还宣布和首尔国立大学进行合作,检测血液中游离的肿瘤DNA。

[原文]

  Sequenom today announced a collaboration with the University of Colorado Denver, School of Medicine to investigate the use of the company's liquid biopsy assay in melanoma patients.
  As part of the collaboration, the partners will evaluate Sequenom's technology to determine whether circulating tumor DNA profiling has use for monitoring treatment response and relapse in melanoma patients.
  Sequenom CMO Daniel Grosu noted that the collaborative study is the firm's first focused on melanoma, and it expands the range of cancers and clinical care settings that Sequenom is exploring for its technology.
  Sequenom is currently developing its research-use-only assay with an initial focus on detecting and molecularly profiling late-stage non-hematologic malignancies. The assay will cover a number of cancers and analyze more than 100 cancer-related genes that are associated with a US Food and Drug Administration-approved drug treatment, included in professional society guidelines, linked to targeted therapies currently in clinical trials, or part of well-documented cancer pathways, the company said.
  The deal is the company's third this month for its liquid biopsy technology. Last week, Sequenom and University Medical Center Hamburg-Eppendorf signed an agreement to evaluate the technology for colorectal cancer. Earlier in the month, the firm announced a collaboration with Seoul National University Hospital to profile circulating cell-free tumor DNA in blood.(转化医学网360zhyx.com)
评论:
评 论
共有 0 条评论

    还没有人评论,赶快抢个沙发

相关阅读